Transcend Capital Advisors, LLC Iovance Biotherapeutics, Inc. Transaction History

Transcend Capital Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	SELL	$7.28 - $11.9 $4,368 - $7,140	-600 Reduced 2.67%	21,900 $205,000
Q2 2024 Jul 02, 2024	BUY	$7.78 - $14.19 $175,050 - $319,275	22,500 New	22,500 $180,000
Q2 2021 Aug 13, 2021	SELL	$16.33 - $33.07 $111,533 - $225,868	-6,830 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$28.67 - $52.59 $64,507 - $118,327	-2,250 Reduced 24.78%	6,830 $216,000
Q4 2020 Feb 12, 2021	BUY	$28.04 - $50.26 $6,617 - $11,861	236 Added 2.67%	9,080 $421,000
Q3 2020 Nov 13, 2020	BUY	$27.75 - $36.3 $245,421 - $321,037	8,844 New	8,844 $291,000

318

244M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $928M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Transcend Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Transcend Capital Advisors, LLC with notifications on news.